Tiny Alpha-Ray seeds aim to zap recurrent prostate cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed locally recurrent prostate adenocarcinoma cancer confined to at least 1 hemi-gland with concordant pathology and imaging findings within 6 months prior to consenting * Targetable lesion by either PSMA PET-CT according to PERCIST v1.0 or by multiparametric MRI according RECIST v1.1 * Patient being considered for focal salvage brachytherapy * Lesion size ≤ 3 cm in the longest diameter * Target lesion technically amenable for full tumor coverage with the Alpha DaRT seeds * Pre-salvage PSA level (rPSA) below \<10 ng/ml * Age ≥ 18 years old * ECOG Performance Status Scale ≤ 2 * Subjects' life expectancy is more than 6 months * Negative metastatic workup on at least standard imaging (CT CAP and bone scan). Other metastatic screening studies allowed in lieu of standard imaging including multiparametric MRI prostate/whole body, PSMA PET, F18 PET or Axumin PET within 3 months before visit 0 * Platelet count ≥100,000/mm3 * Subjects are willing and able to sign an informed consent form. Exclusion Criteria: * N1 or M1 disease * Prior TURP or prostate surgery * Inability to undergo multiparametric MRI (i.e. permanent implanted device incompatible with MRI) * Inability to undergo general or spinal anesthesia * Prior androgen deprivation therapy or systemic chemotherapy for prostate cancer within 3 months before visit 0. * Previous diagnosis of other malignancy \< 3 years of enrollment (excluding non-melanomatous skin cancer) * Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT * High probability of protocol non-compliance (in opinion of investigator) * Subjects not willing to sign an informed consent * Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)